Scholars Central

Conference abstractPublished 8 Sep 2014

Why aren’t biosimilars generics - regulatory challenges

Authors: Adam Sabouni

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biological products, derived from mammalian, bacterial, or from animal origins constitute many of today?s important medications. As numerous patents protecting originator biological products are expiring, the development of ?Generic Biologics? products aka biosimilars become a lucrative and exciting opportunity for many ?traditional generic? and international pharmaceutical companies. Unlike small molecule drugs, generally targeted by the ?traditional generic? industry, biological products are usually highly complex in structure. This presentation will highlight the differences between the regulation covering generic ?small molecule? drugs and biosimilar-based drugs and focus on the regulatory challenges in implementing the new regulations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Adam Sabouni”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels